Back

Bacillus Calmette-Guerin (BCG) vaccination: a global analysis of cost-effectiveness and optimal safety stock

2025-12-15 health economics Title + abstract only
View on medRxiv
Show abstract

BackgroundBacille Calmette-Guerin (BCG) is the most commonly-used vaccination globally, but multi-country cost-effectiveness analyses are outdated and have not considered sequelae in tuberculosis survivors. A rationale is lacking to guide the size of safety stocks. MethodsFor the 110 countries using universal neonatal BCG vaccination, we used a decision tree model to compare the costs and health benefits of status-quo BCG vaccination for children aged 0-4 years in 2023 to a counterfactual where...

Predicted journal destinations